Leaflet FOSTER NEXTHALER 200mcg / 6mcg pressurized inhalation solution

Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: inhalation

Substance: beclomethasone + formoterol (bronchodilator + beta-2 adrenergic agonist)

ATC: R03AK08 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)

Precautions:
Hyperglycemia
Hyperglycemia

This medicine may increase blood sugar.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Cardiac risk / QT prolongation / arrhythmias
Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

Beclometasone + formoterol is a combination of a corticosteroid and a long-acting beta-agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Beclometasone reduces airway inflammation, while formoterol relaxes the smooth muscles of the bronchi, improving airflow.

This combination is administered as an inhaler, usually twice daily, as maintenance therapy to prevent symptoms and exacerbations. It is indicated for patients requiring both inflammation control and bronchodilation.

Common side effects include throat irritation, hoarseness, tremors, and palpitations. In rare cases, severe adverse reactions such as paradoxical bronchospasm or hypokalemia may occur. It is important for patients to follow the prescribed dosage and use the inhaler correctly to maximize treatment benefits.

Beclometasone + formoterol is an effective therapeutic option for managing chronic respiratory diseases, contributing to improved quality of life for patients.

General data about FOSTER NEXTHALER 200mcg / 6mcg

  • Substance: beclomethasone + formoterol
  • Date of latest medicines list: 01-06-2016
  • Product code: W62575001
  • Concentration: 200mcg / 6mcg
  • Pharmaceutical form: pressurized inhalation solution
  • Quantity: 1
  • Product type: Original
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: CHIESI FARMACEUTICI S.P.A. - ITALIA
  • Holder: CHIESI PHARMACEUTICALS GMBH - AUSTRIA
  • Number: 14482/2022/01
  • Shelf life: 20 months

Pharmaceutical forms available for beclomethasone + formoterol

Concentrations available for beclomethasone + formoterol

  • 100mcg/6mcg/dose
  • 200mcg/12mcg
  • 200mcg/6mcg
  • 200mcg/6mcg/dose